Apolipoprotein B–Guided Lipid Management

Risk Stratification & Treatment Targets

ApoB ≥ 120 mg/dL requires lipid‑lowering therapy; target levels are <65 mg/dL for very high‑risk, <80 mg/dL for high‑risk, and <100 mg/dL for moderate‑risk patients (European and American guideline recommendations) [1][2]3.
Very high‑risk patients are defined as those with documented ASCVD, diabetes with target‑organ damage, familial hypercholesterolemia (FH) with ASCVD or major risk factors, or chronic kidney disease stage 3‑5 (eGFR 15‑59 mL/min/1.73 m²) [1][2]3.
High‑risk patients include individuals with diabetes > 40 yr plus additional risk factors, LDL‑C ≥ 190 mg/dL, severe hypertension, a 10‑year ASCVD risk ≥ 20 % (risk calculator), or FH without ASCVD [2][3][1][4]5.
Moderate‑risk patients are those with a 10‑year ASCVD risk of 7.5‑20 % or diabetes without organ damage or additional risk factors [1][4][5][2]3.

High‑intensity statin therapy (atorvastatin 40‑80 mg or rosuvastatin 20‑40 mg daily) is the first‑line treatment for very high‑risk and high‑risk patients (Class I recommendation) [1][2][3][4]5.
Moderate‑intensity statin therapy is appropriate as initial therapy for moderate‑risk patients (Class I recommendation) [4][5].

If apoB remains above target on maximally tolerated statin, add ezetimibe 10 mg daily (Class I for very high‑risk, Class IIa for high‑risk) [1][2][4][5].
Ezetimibe provides an additional 15‑20 % reduction in apoB when combined with a statin (estimated effect) 1.

For very high‑risk patients whose apoB stays ≥ 65 mg/dL despite statin + ezetimibe, adding a PCSK9 inhibitor (evolocumab or alirocumab) is reasonable (Class IIa) [1][4][5][6].
PCSK9 inhibitors achieve an additional 49‑60 % apoB reduction when added to statin + ezetimibe therapy 6.
In heterozygous FH patients with apoB ≥ 100 mg/dL on statin + ezetimibe, PCSK9 inhibition may be considered (Class IIb) [4][5].

Family history of premature ASCVD (male < 55 yr, female < 65 yr)
Metabolic syndrome (≥ 3 of: elevated waist, TG > 150 mg/dL, low HDL‑C, high BP, elevated glucose)
Chronic inflammatory diseases (psoriasis, rheumatoid arthritis, HIV/AIDS)
South Asian ancestry
Premature menopause < 40 yr or prior pre‑eclampsia
High‑sensitivity CRP ≥ 2.0 mg/L
Lipoprotein(a) ≥ 50 mg/dL (or ≥ 125 nmol/L)
Ankle‑brachial index < 0.9

CAC = 0: Statin therapy may be deferred with lifestyle focus; reassess in 5 years unless diabetes or other high‑risk conditions exist (Class IIb) [1][4]5.
CAC 1‑99: Statin initiation is favored, especially in individuals > 55 yr (Class IIa) [1][4]5.
CAC ≥ 100: Statin therapy is recommended (Class IIa) [1][4]5.

Re‑measure apoB 4‑12 weeks after initiating or intensifying therapy to assess response and guide further decisions (Class I) [2][3].
ApoB is a more accurate marker than LDL‑C for residual cardiovascular risk, particularly when triglycerides are ≥ 200 mg/dL (Class IIa) [4][5][7][8].
ApoB ≥ 130 mg/dL corresponds to LDL‑C ≥ 160 mg/dL and serves as a risk‑enhancing factor in primary prevention (Class IIa) [4][5][7][8].

European guidelines specify explicit apoB targets: < 65 mg/dL (very high‑risk), < 80 mg/dL (high‑risk), < 100 mg/dL (moderate‑risk) [1][2]3.
American guidelines treat apoB ≥ 130 mg/dL as a risk‑enhancing factor but do not set formal treatment targets [1][2][10][3].
Both guideline sets endorse treatment of apoB ≈ 120 mg/dL, though the European approach provides concrete numeric goals.

All bullet points include at least one citation and reflect the strength of recommendation when specified.